Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 27;13:10829–10840. doi: 10.2147/OTT.S248492

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Yuan et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Loss of PRIM2 sensitizes NCI-H23 cells to DHA therapy. (A–C) The cell viability and colony formation ability of NCI-H23 cells were detected by CCK-8 assay and colony formation assay. (D–F) Measurement of cellular GSH, cellular ROS and mitochondrial MDA in NCI-H23 cells. (G) The protein expressions of SLC7A11 and β-catenin were analyzed by Western blotting assay. (H) The expression of PRIM2 in LUAD was analyzed by TCGA data using starBase database. The experiments were repeated for three times. Compared with 40 μM DHA treated and Negative control shRNA transfected cells: *p < 0.05, **p < 0.01, ***p < 0.001.